Survodutide: GLP-1/Glucagon Dual Agonist Landscape

Survodutide is an investigational once-weekly injection from Boehringer Ingelheim that combines two gut-hormone signals, GLP-1 and glucagon. It is being developed for obesity, type 2 diabetes and fatty liver disease (MASH). This survodutide landscape article summarizes what has been reported as of November 4, 2026, including a cardiovascular outcomes trial that is scheduled for presentation on November 9.

Mechanism at a glance

Survodutide is a dual agonist: it activates the GLP-1 receptor, the target of the semaglutide and tirzepatide drug class, and the glucagon receptor. Boehringer has sole responsibility for global development and commercialization, while Zealand Pharma is eligible for royalties and milestones. In its Phase 3 trials the drug was given weekly at 3.6 mg or 6.0 mg. Gastrointestinal side effects, as with other GLP-1-based drugs, were the main tolerability issue reported so far.

Why it matters

Obesity is the most crowded area of cardiometabolic drug development, and the question for every newcomer is where it fits. Survodutide’s distinguishing bet is the liver: it has FDA Breakthrough Therapy designation for MASH with fibrosis. Its Phase 3 obesity data are now largely in, and it has not been approved anywhere. Boehringer’s releases did not give a timeline for regulatory filings in obesity.

Competitive pressure points

• Weight-loss benchmarks: in SYNCHRONIZE-1 (725 adults without diabetes, 76 weeks) the companies reported up to 16.6% mean weight loss versus 3.2% on placebo, by the efficacy estimand. In SYNCHRONIZE-2 (755 adults with type 2 diabetes) the figure was up to 13.1% versus 3.1%. These are not head-to-head comparisons with other drugs.
• Tolerability: in SYNCHRONIZE-2, discontinuations for gastrointestinal events were 18% versus 1.2% on placebo, mostly during dose escalation. Boehringer says future studies will use more individualized titration.
• Retatrutide (Lilly): Lilly reported on July 23, 2026 that, at 80 weeks, TRIUMPH-3 patients lost 21.6% (9 mg) and 22.6% (12 mg) of body weight versus 3.2% on placebo, and plans to submit to the FDA in the first quarter of 2027.
• Oral options: the FDA approved Lilly’s orforglipron (Foundayo) on April 1, 2026, about three months after oral semaglutide (the Wegovy pill) on December 22, 2025.
• CagriSema (Novo Nordisk): submitted to the FDA in December 2025, with a decision expected by late 2026. In REDEFINE 4 it did not show non-inferiority to tirzepatide 15 mg (23.0% versus 25.5% weight loss when adhering to treatment).
• MASH: Madrigal’s Rezdiffra was approved in 2024, and Wegovy received an accelerated FDA approval for noncirrhotic MASH with moderate-to-advanced fibrosis in August 2025.

What to watch

• The SYNCHRONIZE-CVOT results: a cardiovascular safety trial in adults with overweight or obesity (NCT06077864) with about 5,530 participants.
• Whether Boehringer announces filing plans in obesity and type 2 diabetes after the full data set is in.
• LIVERAGE timelines: the registry lists primary completion in 2031 for the fibrosis trial and 2029 for the cirrhosis trial.
• Tolerability under the planned individualized titration.

For related context, see our articles on retatrutide, orforglipron, and obesity trial volume.

Recent developments

Updated November 4, 2026. Items are drawn from company announcements, regulators and trade press; links go to the sources.

• Oct 1, 2026: SYNCHRONIZE-2 was presented at EASD and published in NEJM. Boehringer said it expects to present SYNCHRONIZE-CVOT later in 2026 and that a new Phase 3 trial, SYNCHRONIZE-T2D, has started. (AJMC)
• Jun 2026: At ADA, SYNCHRONIZE-MASLD (218 adults) reported that 84.2% on survodutide had at least a 30% relative liver-fat reduction at week 48 versus 24.3% on placebo; results were published in Nature Medicine. (Managed Healthcare Executive)
• Apr 28, 2026: Zealand and Boehringer reported SYNCHRONIZE-1 topline results: both co-primary endpoints met, with 85.1% of survodutide patients losing at least 5% of body weight versus 38.8% on placebo. (Zealand Pharma via BioSpace)

Upcoming catalysts

• Nov 9, 2026, 8:00 a.m.: SYNCHRONIZE-CVOT is listed in the AHA Scientific Sessions late-breaking session on cardiometabolic risk reduction in Chicago. (TCTMD)
• Q1 2027: Lilly plans to submit retatrutide to the FDA. (Lilly via BioSpace)
• Late 2026: expected FDA decision on CagriSema; no PDUFA date confirmed in the sources reviewed. (Novo Nordisk)
• 2029 and 2031 (estimated): primary completion of LIVERAGE-Cirrhosis and LIVERAGE.

Bottom line

Survodutide has delivered substantial weight loss in two Phase 3 trials, but its reported figures are lower than those Lilly reported for retatrutide (different trials and populations, so not a direct comparison) and come with notable early gastrointestinal discontinuations. Its differentiation case rests on the liver program and on the cardiovascular outcomes data due this week.

No SYNCHRONIZE-CVOT results were public as of November 4, 2026, so any interpretation of them has to wait for the presentation.

Want this kind of analysis for the cardiovascular and metabolic areas you compete in? Request information and we will share sample deliverables.

This article is for informational and competitive-intelligence purposes only and is not medical advice. Approvals, labels and trial results change; verify details against current prescribing information and primary sources.